Search Results - "Saevets, Valeriya"

Clinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study by Saevets, Valeriya V., Shamanova, Anna Yu

“…Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor…”
Get full text

MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy (334) by Saevets, Valeriya, Yin, Rutie, Zhu, Jianqing, Chen, Chris, Zhang, Jing, Ah-See, Mei-Lin, Wu, Xiaohua

Get full text

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial by Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J, Contreras Mejía, Fernando, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro, Duska, Linda R

“…Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy…”
Get full text

Cost-effectiveness of using granulocyte colony-stimulating factor in the treatment of uterine body leiomyosarcomas. A retrospective analysis by Saevets, Valeriya V., Kuzmin, Nikita K., Shamanova, Anna Yu, Mukhin, Arsentiy A., Taratonov, Alexey V.

“…Background. The main approach in the treatment of patients with uterine leiomyosarcoma is surgery followed by chemotherapy, which is the basis of treatment…”
Get full text

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study by Duska, Linda, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Elias, Pier Anyelo, Acevedo, Alejandro, Vizkeleti, Julia, Gomes, Andrea Juliana, Mejía, Fernando Contreras, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Li, Kan, Yamada, Karin, Toker, Sarper, Pignata, Sandro, Lorusso, Domenica

Get full text

Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer by Randall, Leslie, Sukhin, Vladyslav, Colombo, Nicoletta, Korach, Jacob, Matsumoto, Takashi, Lalondrelle, Susan, Vizkeleti, Julia, Samouelian, Vanessa, Salani, Ritu, Salman, Pamela, Nogueira-Rodrigues, Angelica, Ayhan, Ali, Frentzas, Sophia, Cueva, Juan, Kim, Yong-Man, Petru, Edgar, Milla, Dency Pilar, Sehouli, Jalid, Saevets, Valeriya, Yamada, Karin, Li, Kan, Szamreta, Elizabeth, Nguyen, Allison Martin, Pignata, Sandro, Lorusso, Domenica

Get full text

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial by Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Cvek, Jakub, Randall, Leslie, Pereira de Santana Gomes, Andrea Juliana, Contreras Mejía, Fernando, Helpman, Limor, Akıllı, Hüseyin, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Colombo, Nicoletta, Chang, Chih-Long, Bednarikova, Marketa, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Petru, Edgar, Usami, Tomoka, Liu, Peng, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro, Duska, Linda R

“…At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically…”
Get full text

Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial by Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J., Mejía, Fernando Contreras, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M., Pignata, Sandro, Duska, Linda R.

“…(Abstracted from Lancet 2024;403:1341–1350) Prognosis for locally advanced cervical cancer is poor, with 5-year progression-free survival (PFS) and overall…”
Get full text